Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Bypass without surgery: new scope procedure helps cancer patients eat again

NCT ID NCT05644951

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new procedure that uses an endoscope to create a bypass around a stomach blockage caused by advanced cancer. The goal was to help people eat and drink without major surgery. Fifty-one participants with inoperable cancer and severe blockage were enrolled. The procedure uses a special device to connect the stomach directly to the small intestine, bypassing the blocked area.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Hot AXIOS system (a device used to create a bypass between the stomach and small intestine)
What this could lead to
If successful, this procedure could offer a less invasive way to relieve stomach blockage in people with advanced cancer, allowing them to eat and drink more easily.
What could go wrong
This was a small, single-arm study with no comparison group, so results may not apply to everyone. The procedure carries risks like bleeding, infection, or device-related problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

51 people

The number who actually took part.

Started

Dec 2022

Finished

Aug 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Unresectable malignant duodenal obstruction confirmed by biopsy * Eligible for endoscopic intervention * GOOSS score of 0 or 1 * 18 years of age or older * Willing and able to comply with the study procedures or legally authorized representative (LAR) must provide written informed consent form (ICF) to participate in the study Exclusion Criteria: * GOO symptoms are not expected to improve after the index procedure * Life expectancy is about 3 months or less, which is not assumed applicable for surgical GJ * Prior metallic stent placement for GOO * Contraindicated to surgery and general anesthesia * Neoplasm invading the target site of puncture in gastric and/or jejunum * Abnormal coagulation INR \> 1.5 and not correctable (per the discretion of the physician) or who require continuous complete anticoagulation * Bleeding diathesis * Altered anatomy of the upper gastrointestinal tract due to surgery of esophagus, stomach and duodenum that might preclude endoscopic drainage * Presence of ileus caused by peritoneal carcinomatosis, or expected to present within 30 days post procedure * Intervening gastric varices or vessels at the target site of stent insertion * Ascites that may interfere the safety of the index procedure * Biliary tract obstruction requiring treatment at the same day of the index procedure * Allergic to any of the device materials * Contraindications to use of electrosurgical devices * Pregnancy, breastfeeding or intending to become pregnant during the study period * Subject is currently participating, or plans to participate in, another investigational trial that may confound the results of this trial (unless written approval is received from the study sponsor) * Vulnerable subject * Subject has other reason not to be eligible for this study per investigators' discretion * Guidewire doesn't cross the area of GOO * EP-DB doesn't advance to the target site in jejunum * The distance between the gastric wall and jejunal wall when visualized on ultrasound after saline is introduced into the space between the two inflated balloons of EP-DB is deemed about 2 cm or more

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastric outlet obstruction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Aichi Cancer Center Hospital

    Nagoya, Aichi-ken, 4648681, Japan

  • Cancer Institute Hospital of JFCR

    Koto-Ku, Tokyo, 1350063, Japan

  • Saitama Medical University International Medical Center

    Hidaka, Saitama, 3501241, Japan

  • Teine Keijinkai Hospital

    Sapporo, Hokkaido, 0060829, Japan

  • The University of Tokyo Hospital

    Bunkyō-Ku, Tokyo, 1130033, Japan

  • Tokyo Medical University Hospital

    Shinjuku-Ku, Tokyo, 1600023, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.